thymosin and bpc 157 BPC-157 / TB-500 Blend | Research Peptide Combination Thymosin A-1 | Next Gen

For an introduction to our Peptide & Regenerative Medicine Performance Team, email [email protected] and well point you in the right direction.

Laboratory protocols demonstrate that the peptide neutralizes doxorubicin-induced chemotoxicity and shows that research targeting of senescent cells is feasible even after health decline has occurred

This process removes water under vacuum at low temperatures, making the peptide stable for shipping and storage

It has been studied for potential roles in healing and mobility

The action of TB-500 tends to be systemic: it distributes broadly after injection and influences tissues that are considerably remote from the injection site

This activation leads to enhanced dopamine synthesis and release, potentially compensating for the loss of dopaminergic neurons in Parkinsons disease